Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention.

New priority program opens up exclusive opportunities for collaborative research on transformative clinical potential of DNAe's flagship tests and to gain ...

Acute myeloid leukemia (AML) is an aggressive blood cancer, with overall survival remaining approximately 30% at five years ...

Zurletrectinib has been included in the “SPARK Program” by China’s National Medical Products Administration (NMPA), a pilot initiative to encourage the development of pediatric anti-tumor drugs.